FABAC-Thyroid Agonist Combination for Liver Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and fibrosis are ineffective and often associated with toxicity and side effects, highlighting an unmet medical need for safe and effective therapeutic interventions.
Innovation Solution
A therapeutic combination of fatty acid-bile acid conjugates (FABACs) and thyroid hormone receptor agonists or mimetics, administered together to treat, stabilize, or reduce the severity or progression of liver diseases, including NAFLD, NASH, and fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for liver diseases are used, then some therapeutic effect may be achieved, but toxicity and side effects occur
Solution Approach 1:
The patent combines two distinct therapeutic agents with different mechanisms of action: fatty acid-bile acid conjugates (which reduce hepatic steatosis through bile acid signaling) and thyroid hormone receptor agonists (which increase metabolic rate and lipid oxidation). This combination creates a synergistic effect that improves therapeutic efficacy while allowing lower doses of each individual agent, thereby reducing toxicity and side effects compared to monotherapy at higher doses.
2Duration of action of moving object
If available treatments for fatty liver disease are used, then some symptom relief may be achieved, but long term treatment is limited by toxicity and side effects
Solution Approach 1:
The patent changes the dosing parameters by using lower doses of each individual agent in combination, rather than high doses of a single agent. This parameter change allows for long-term treatment sustainability because the reduced individual doses minimize cumulative toxicity and side effects, enabling patients to maintain therapy over extended periods without treatment discontinuation due to adverse effects.
3Reliability
If monotherapy with single agents is used, then treatment simplicity is maintained, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent merges two orally administrable agents into a single combination therapy regimen. Both the fatty acid-bile acid conjugate and thyroid hormone receptor agonist can be administered together in a single daily dose, maintaining treatment simplicity from the patient's perspective while achieving superior therapeutic efficacy through the complementary mechanisms of action of the two agents.
Data Source
AI summary
The invention relates to pharmaceutical compositions, and more specifically to pharmaceutical compositions comprising at least one fatty acid-bile acid conjugate and at least one thyroid hormone receptor agonist or thyroid hormone mimetic or pharmaceutically acceptable salts thereof, and use of such compositions in methods of treating, stabilizing or lessening the severity or progression of a liver disease including fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and comorbidity ties associated with a liver disease.